Group 1 - The company is developing a small molecule peptide drug for obesity and diabetes, currently in the preclinical stage with promising preliminary data and plans for clinical transition [2] - The drug's mechanism and target differ from GLP-1 drugs like Semaglutide, showing significant weight loss efficiency in diabetic obese mouse studies compared to Semaglutide [2] - The drug not only aids in weight loss and fat burning but also reduces muscle loss, lowers blood sugar, has anti-inflammatory effects, and improves various metabolic indicators [2] Group 2 - The company will fulfill its information disclosure obligations regarding any external collaborations based on progress, with specific announcements to follow [2]

Core Viewpoint - Wanbangde (002082) is advancing a small molecule peptide new drug targeting obesity and diabetes, currently in the preclinical stage with promising preliminary data, and plans to move towards clinical translation [1] Group 1: Drug Development - The small molecule peptide new drug is in the preclinical stage for indications such as obesity and diabetes [1] - Preliminary data shows that the drug not only aids in weight loss and fat burning but also reduces muscle loss, lowers blood sugar, has anti-inflammatory effects, and improves multiple metabolic indicators [1] - In studies involving diabetic obese mice, the weight loss efficiency of this drug significantly outperformed that of Semaglutide, a GLP-1 class drug [1] Group 2: Mechanism of Action - The drug has a different target and mechanism of action compared to GLP-1 drugs like Semaglutide [1]